Download MendeleyDiscovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Graham, K., Lienau, P., Bader, B., Prechtl, S., Naujoks, J., Lesche, R., Weiske, J., Kuehnlenz, J., Brzezinka, K., Potze, L., Zanconato, F., Nicke, B., Montebaur, A., Bone, W., Golfier, S., Kaulfuss, S., Kopitz, C., Pilari, S., Steuber, H., Hayat, S., Kamburov, A., Steffen, A., Schlicker, A., Buchgraber, P., Braeuer, N., Font, N.A., Heinrich, T., Kuhnke, L., Nowak-Reppel, K., Stresemann, C., Steigemann, P., Walter, A.O., Blotta, S., Ocker, M., Lakner, A., von Nussbaum, F., Mumberg, D., Eis, K., Piccolo, S., Lange, M.(2024) Cell Chem Biol
- PubMed: 38537632
- DOI: https://doi.org/10.1016/j.chembiol.2024.02.013
- Primary Citation of Related Structures:
8RDX - PubMed Abstract:
This study describes the identification and target deconvolution of small molecule inhibitors of oncogenic Yes-associated protein (YAP1)/TAZ activity with potent anti-tumor activity in vivo. A high-throughput screen (HTS) of 3.8 million compounds was conducted using a cellular YAP1/TAZ reporter assay. Target deconvolution studies identified the geranylgeranyltransferase-I (GGTase-I) complex as the direct target of YAP1/TAZ pathway inhibitors. The small molecule inhibitors block the activation of Rho-GTPases, leading to subsequent inactivation of YAP1/TAZ and inhibition of cancer cell proliferation in vitro. Multi-parameter optimization resulted in BAY-593, an in vivo probe with favorable PK properties, which demonstrated anti-tumor activity and blockade of YAP1/TAZ signaling in vivo.
Organizational Affiliation:
Bayer AG, Pharmaceuticals, Research & Development, Muellerstr. 178, 13353 Berlin, Germany; Nuvisan ICB GmbH, Muellerstr. 178, 13353 Berlin, Germany.
